A Phase 1b Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adult Participants
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2019
Price : $35 *
At a glance
- Drugs HIV vaccine (Primary) ; DNA vaccines
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 20 Dec 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 31 Aug 2018 Biomarkers information updated
- 08 May 2018 Planned initiation date changed from 11 Jul 2018 to 1 Jan 2019.